BRIDGEWATER, N.J.--(BUSINESS WIRE)--Asana BioSciences, LLC today announced that preclinical and early clinical data from its ongoing Phase I/II trial of ASN002, the company’s potent oral inhibitor of spleen kinase (SYK) and the Janus kinase (JAK) family, will be presented at the 57th American Society of Hematology (ASH) annual meeting and exposition being held December 5 - 8 in Orlando, Florida. The presentation details are as follows:
